Loading stock data…
SELLAS Life Sciences Group, Inc (SLS)
$15.45+3.06 (+24.70%)
Market ClosedLast close Jun 29
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SELLAS Life Sciences Group, Inc. in the Healthcare sector is trading at $15.45 with a market capitalization of $1.6B. Wall Street consensus targets $10.00 (2 analysts), implying a -35.3% move over the next 12 months. The stock is currently near its 52-week high of $15.67, remaining 270.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -35.3% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.25M↓ | -$8.26M↓ | -$7.08M↓ | -$6.87M↓ | -$6.06M |
| Net Income | -$8.41M↓ | -$7.66M↓ | -$6.79M↓ | -$6.60M↓ | -$5.81M |
Peer Comparison
JNJUNHPFE
Fundamentals
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a p...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.61B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.42%
Volume
Today's trading volume
31.94M
Recent News
Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today?
Sellas Life Sciences, BlackBerry, and Ouster rallied to 52-week highs on Monday as investors rotated into the companies amid positive catalysts.
SLS Stock Hits Over 5-Year High: Retail Traders Bet Big On Breaking $25 As AML Readout Looms
Recently updated change-of-control terms also fueled buyout chatter by outlining executive payouts and full equity acceleration related to a change in control.
Is SELLAS Life Sciences Group, Inc. (SLS) A Good Stock To Buy Now?
Is SLS a good stock to buy? We came across a bullish thesis on SELLAS Life Sciences Group, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on SLS. SELLAS Life Sciences Group, Inc.’s share was trading at $9.07 as of June 23rd. SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical […]
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology
XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.